Literature DB >> 15549216

[Pharmacological treatment in adults with attention deficit hyperactivity disorder].

J Frölich1, G Lehmkuhl.   

Abstract

Treatment in adults with attention deficit hyperactivity disorder predominantly relies on pharmacotherapeutic approaches especially with psychostimulants. Empirical studies indicate that their clinical effectiveness may be as high as in children and adolescents, especially in higher dosages. However, due to the high prevalence of comorbidities, e.g. depression, psychopharmacological treatment requires an extended use of other substance groups, especially antidepressants. An optimal treatment response necessitates the choice of an adequate substance depending on the leading clinical symptoms and a procedure of an individual titration of different dosages. This article reviews the current empirical results in the pharmacological treatment of ADHD in adults and provides possible treatment strategies for clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549216     DOI: 10.1007/s00115-004-1756-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  72 in total

1.  Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; J Prince; M Hatch; J Jones; M Harding; S V Faraone; L Seidman
Journal:  Am J Psychiatry       Date:  1998-05       Impact factor: 18.112

2.  Intranasal abuse of prescribed methylphenidate.

Authors:  E J Garland
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1998-06       Impact factor: 8.829

3.  More frequent diagnosis of attention deficit-hyperactivity disorder.

Authors:  J M Swanson; M Lerner; L Williams
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

4.  Clinical correlates of methylphenidate blood levels.

Authors:  C T Gualtieri; R E Hicks; K Patrick; S R Schroeder; G R Breese
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

Review 5.  Catecholamines in attention-deficit hyperactivity disorder: current perspectives.

Authors:  S R Pliszka; J T McCracken; J W Maas
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-03       Impact factor: 8.829

6.  A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Authors:  W E Pelham; H R Aronoff; J K Midlam; C J Shapiro; E M Gnagy; A M Chronis; A N Onyango; G Forehand; A Nguyen; J Waxmonsky
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

7.  The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.

Authors:  M F Ward; P H Wender; F W Reimherr
Journal:  Am J Psychiatry       Date:  1993-06       Impact factor: 18.112

8.  An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder.

Authors:  D Hedges; F W Reimherr; A Rogers; R Strong; P H Wender
Journal:  Psychopharmacol Bull       Date:  1995

9.  Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey.

Authors:  D H Langer; K P Sweeney; D E Bartenbach; P M Davis; K B Menander
Journal:  Drug Alcohol Depend       Date:  1986-06       Impact factor: 4.492

10.  Propranolol for adults with temper outbursts and residual attention deficit disorder.

Authors:  J A Mattes
Journal:  J Clin Psychopharmacol       Date:  1986-10       Impact factor: 3.153

View more
  1 in total

1.  A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial.

Authors:  Salvatore Corbisiero; Hannes Bitto; Patricia Newark; Beatrice Abt-Mörstedt; Marina Elsässer; Jacqueline Buchli-Kammermann; Sven Künne; Elisabeth Nyberg; Maria Hofecker-Fallahpour; Rolf-Dieter Stieglitz
Journal:  Front Psychiatry       Date:  2018-11-16       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.